EVENT REPLAY NOW AVAILABLE
Recorded June 28, 2024
Nusano and LifeSci Advisors invite you to go back to school…
Join us on Friday, June 28, 2024 from 11:30 a.m. to 12:30 p.m. Eastern for Office Hours: Radiopharmaceuticals.
This informative discussion will explain how foundational physics and chemistry are applied in real-world settings.
Dr. Suzanne Lapi (University of Alabama at Birmingham) will describe the scientific principles underlying the rapidly emerging field of radiotherapeutics in a format that will be of interest to both scientists and non-scientists.
Helping connect these scientific concepts to market trends, will be Kemp Dolliver of Brookline Capital Markets. Mr. Dolliver, the author of Radiopharma Roundup, is an accomplished healthcare finance executive with extensive experience in the capital markets. He has held buy-side and sell-side roles in both the US and emerging Asia, focused on biopharma and healthcare services.
Key topics in this discussion-style event will include medical radioisotope production, the importance of linker chemistry in pharmaceutical development, and a look ahead at where the field is going now that major pharmaceutical firms have paid billions to get into the game.
Don’t miss out! This is everything you should have learned in college, forgot, or were too afraid to ask.
Registration information
You are required to register in advance for the webcast. For those who are unable to attend live, a replay will be available afterward.
Q&A information
If you would like to ask a question during the live Q&A, please submit your request to communications@nusano.com.
SPEAKER BIOGRAPHIES
Suzanne Lapi
Suzanne E. Lapi, Ph.D. is the Emmet O’Neal II Professor, O’Neal Comprehensive Cancer Center and Professor of Radiology and Chemistry and Cyclotron Facility Director at the University of Alabama at Birmingham. She is also the Vice Chair of Research in the Department of Radiology. Her research interests are in the development and translation of new PET radionuclides and molecular imaging agents. She has over 150 publications and is PI on active research grants from NIH and DOE as well as industry partners. She oversees production of PET radionuclides and imaging radiopharmaceuticals for preclinical research and clinical trials. Her group holds >15 approved INDs and supplies Cu-64, Zr-89, Mn-52 and other isotopes to groups across the USA and internationally. She is a Fellow of the SNMMI and a strong advocate of radiopharmaceutical sciences and the training of future nuclear and radiochemists at the graduate, postdoctoral and faculty levels.
Kemp Dolliver
Kemp Dolliver is the Director of Research and a Senior Analyst at Brookline. Mr. Dolliver has extensive healthcare experience across multiple sell-side and buy-side roles in the U.S and Asia. Previously, he was the Founder and Chief Investment Officer of Cherrystone Hill Capital Management, LLC, which specialized in investing in listed healthcare companies throughout the world’s emerging markets. As a sell-side analyst, Mr. Dolliver was a Managing Director at Religare Capital Markets Pte. Ltd., Avondale Partners LLC, and Cowen Inc. His buy-side roles have included portfolio management positions at both Aetna and Bank of America. The Wall Street Journal has recognized him four times for his stock picking abilities in its “Best on the Street” survey. Mr. Dolliver received a B.S. in Commerce from the McIntire School of Commerce, where he currently serves on the Advisory Board, and an M.B.A. from the Darden School of Business at the University of Virginia.
